Anti-IL-23 (p19)Injection sous-cutanéeAbbVie
Skyrizi®
DCI : Risankizumab
Anticorps anti-IL-23 (p19). 150 mg SC à S0, S4 puis toutes les 12 semaines.
Pharmacovigilance — Top effets indésirables
4 185 rapports FAERS- PRODUCT STORAGE ERROR907 (35%)
- Inefficacité du traitement283 (11%)
- Utilisation hors AMM187 (7%)
- PSORIASIS183 (7%)
- PRODUCT TEMPERATURE EXCURSION ISSUE178 (7%)
- CROHN^S DISEASE147 (6%)
- Arthralgies134 (5%)
- Diarrhée100 (4%)
- Fatigue97 (4%)
- Céphalées88 (3%)
- Prurit81 (3%)
- Douleur abdominale80 (3%)
- Rash cutané80 (3%)
- THERAPEUTIC PRODUCT EFFECT INCOMPLETE74 (3%)
Source : OpenFDA / FAERS (FDA Adverse Event Reporting System). Termes MedDRA traduits FR. Les rapports incluent des attributions causales non confirmées.
Avis HAS — Commission de la Transparence
Source HAS via Google News RSS · avis SMR/ASMR officiels.